Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Single arm phase II trial designed to assess the efficacy of durvalumab treatment in terms of
6-month progression-free survival. We will include 22 patients who will receive 1500 mg
durvalumab (MEDI4736) via IV infusion Q4W <> or <> unless there is unacceptable toxicity, withdrawal of consent, or another
discontinuation criterion is met. If a patient's weight falls to 30 kg or below for 1 week or
longer ( ≥ 7 days) durvalumab will be permanently discontinued.